GLP-1 drugs cut heart attack, stroke risk in major study

A major study found GLP-1 users had lower risks of heart attack and stroke, with effects beyond blood sugar control. The lead author expected improved glycemic control versus metformin, but cardiovascular benefits were less predictable. This strengthens the case for broader cardiometabolic use of GLP-1s, though the study's design and population specifics remain unclear.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works